Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer
نویسندگان
چکیده
منابع مشابه
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
OBJECTIVE To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS Postmenopausal women (n = 1,286) with HR(+) MBC were randomized to daily oral treatment with letrozole ...
متن کاملHER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Trastuzumab with a taxane as first-line therapy is now the standard of care for patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (MBC). The search for additional and more effective trastuzumab-based therapies continues. Novel combinations of trastuzumab with chemotherapeutic agents, including vinorelbine, gemcitabine, and capecitabine, and hormona...
متن کاملPalbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor–Positive, HER2-Negative Breast Cancer
© 2015 Harborside Press® B reast cancer is the second leading cause of cancer-related death in American women. However, mortality has been steadily decreasing due to improvements in early detection and advances in treatment (American Cancer Society, 2015). Clinicians consider tumor histology along with the extent of disease and patient characteristics such as age, menopausal status, and comorbi...
متن کاملTreatment Considerations for the Management of Patients With Hormone Receptor–Positive Metastatic Breast Cancer
Breast cancer is among the most commonly diagnosed cancers in the United States. Despite treatment, 30% to 40% of women with early-stage or localized invasive breast cancer will eventually develop metastatic disease. Women with metastatic breast cancer (MBC) are living longer lives with the advent of new therapies. Currently, treatment for MBC can consist of a variety of approaches including ch...
متن کاملPalbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 that acts by reducing phosphorylation of the tumor suppressor gene retinoblastoma. When added to the aromatase inhibitor letrozole in a randomized phase II trial for first-line therapy of estrogen receptor-positive, HER2-negative metastatic breast cancer, palbociclib significantly increased progression-free survival compar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Oncology
سال: 2019
ISSN: 1479-6694,1744-8301
DOI: 10.2217/fon-2018-0086